Next Article in Journal / Special Issue
Personalized 3-Gene Panel for Prostate Cancer Target Therapy
Previous Article in Journal
The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia
Previous Article in Special Issue
Circulating Exosomal miR-1290 for Diagnosis of Epithelial Ovarian Cancer
 
 
Article

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

1
Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
2
Department of Cancer Prevention and Therapy, Wroclaw Medical University, 50-556 Wrocław, Poland
3
Department of Haematology, Sokołowski Specialist Hospital, 58-309 Wałbrzych, Poland
4
Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wrocław, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Dumitru A. Iacobas
Curr. Issues Mol. Biol. 2022, 44(1), 350-359; https://doi.org/10.3390/cimb44010026
Received: 25 November 2021 / Revised: 8 January 2022 / Accepted: 10 January 2022 / Published: 14 January 2022
(This article belongs to the Special Issue Molecules at Play in Cancer)
CD147 (basigin, BSG) is a membrane-bound glycoprotein involved in energy metabolism that plays a role in cancer cell survival. Its soluble form is a promising marker of some diseases, but it is otherwise poorly studied. CD147 is overexpressed in multiple myeloma (MM) and is known to affect MM progression, while its genetic variants are associated with MM survival. In the present study, we aimed to assess serum soluble CD147 (sCD147) expression as a potential marker in MM. We found that sCD147 level was higher in MM patients compared to healthy individuals. It was also higher in patients with more advanced disease (ISS III) compared to both patients with less advanced MM and healthy individuals, while its level was observed to drop after positive response to treatment. Patients with high sCD147 were characterized by worse progression-free survival. sCD147 level did not directly correlate with bone marrow CD147 mRNA expression. In conclusion, this study suggests that serum sCD147 may be a prognostic marker in MM. View Full-Text
Keywords: BSG; basigin; CD147; MM; multiple myeloma; survival BSG; basigin; CD147; MM; multiple myeloma; survival
Show Figures

Figure 1

MDPI and ACS Style

Łacina, P.; Butrym, A.; Frontkiewicz, D.; Mazur, G.; Bogunia-Kubik, K. Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma. Curr. Issues Mol. Biol. 2022, 44, 350-359. https://doi.org/10.3390/cimb44010026

AMA Style

Łacina P, Butrym A, Frontkiewicz D, Mazur G, Bogunia-Kubik K. Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma. Current Issues in Molecular Biology. 2022; 44(1):350-359. https://doi.org/10.3390/cimb44010026

Chicago/Turabian Style

Łacina, Piotr, Aleksandra Butrym, Diana Frontkiewicz, Grzegorz Mazur, and Katarzyna Bogunia-Kubik. 2022. "Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma" Current Issues in Molecular Biology 44, no. 1: 350-359. https://doi.org/10.3390/cimb44010026

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop